Cost of innovation making fight against superbugs near impossible
Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.
Research & Development
Study: Cancer, orphan drugs dominate pharma launches, R&D in 2018
IQVIA examined the research and development landscape of 2018.
WPP Health Practice teams up with London School of Hygiene & Tropical Medicine
The holding company health unit will work with the university on its initiatives around the world.
Continued research depends on fair prices for treatments
Sander Flaum explains why continued research depends on fair prices for treatments.
Three data architects share the secrets of their universe
Three of the industry’s top data architects reflect on their careers, opine on pharma’s “data revolution,” muse on the future of AI in healthcare, and unravel the secrets of their universe.
The caregiver’s journey is a highly personal one. A study examined their role in treatment decisions
Caregivers are intimately involved in patient health, and that includes deciding on treatments, a new study suggests.
Vanessa Thirion-Cullity, Novartis Oncology
Vanessa Thirion-Cullity is executive director, U.S. NET of Novartis Oncology.
Deborah Profit, Ostuka
Deborah Profit is VP, Otsuka Information Technology at Ostuka.
Elena Cant, Takeda
Elena Cant is VP, global head of vaccine commercial, Takeda Vaccine Business Unit of Takeda.
Alisa Lask, Galderma
Alisa Lask is VP and GM, U.S. aesthetic business unit of Galderma, Nestlé Skin Health.
